Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb)
Bevacizumab（Arketin）, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb), specifi_x005fcally binds to VEGF to prevent VEGF from binding to its receptor, thereby reducing neovascularization, inducing degeneration of existing blood vessels and inhibiting tumor growth. As a broad-spectrum anti-tumor agent, bevacizumab is a standard regimen recommended in treatment guidelines for various malig_x0002_nancies worldwide. Since entering the market, its efficacy and safety have been widely demonstrated in clinical practice.
Indications
Metastatic colorectal cancer.
Advanced, metastatic, or recurrent non-small cell lung cancer.
Recurrent glioblastoma.
Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Cervical cancer
Strength
100mg/vial
Recommended reading
How to choose a suitable bevacizumab biosimilar manufacturer?
Download instructions
Contact us